Nifty 17469.75 (1.71%)
Sensex 58649.68 (1.76%)
Nifty Bank 37284.7 (1.82%)
Nifty IT 35959.05 (1.95%)
Nifty Financial Services 18284.95 (1.70%)
Adani Ports 761.40 (2.24%)
Asian Paints 3108.50 (2.58%)
Axis Bank 697.10 (1.47%)
B P C L 391.15 (0.86%)
Bajaj Auto 3332.05 (1.39%)
Bajaj Finance 7361.50 (3.64%)
Bajaj Finserv 17621.65 (3.00%)
Bharti Airtel 715.15 (2.33%)
Britannia Inds. 3575.75 (2.92%)
Cipla 897.95 (0.98%)
Coal India 150.90 (0.17%)
Divis Lab. 4604.95 (-0.43%)
Dr Reddys Labs 4570.70 (1.11%)
Eicher Motors 2505.55 (1.37%)
Grasim Inds 1716.25 (1.82%)
H D F C 2853.00 (1.26%)
HCL Technologies 1171.60 (1.91%)
HDFC Bank 1553.80 (1.84%)
HDFC Life Insur. 686.40 (-1.15%)
Hero Motocorp 2490.65 (1.17%)
Hind. Unilever 2340.60 (0.82%)
Hindalco Inds. 457.45 (3.38%)
I O C L 120.40 (-0.17%)
ICICI Bank 753.40 (2.55%)
IndusInd Bank 945.30 (2.01%)
Infosys 1753.35 (2.44%)
ITC 224.95 (1.95%)
JSW Steel 672.95 (1.86%)
Kotak Mah. Bank 1920.45 (-0.86%)
Larsen & Toubro 1825.05 (1.50%)
M & M 840.75 (1.79%)
Maruti Suzuki 7434.90 (3.46%)
Nestle India 19479.10 (0.70%)
NTPC 127.25 (1.52%)
O N G C 148.40 (1.71%)
Power Grid Corpn 204.80 (-0.49%)
Reliance Industr 2418.10 (1.52%)
SBI Life Insuran 1169.50 (0.89%)
Shree Cement 26106.90 (1.40%)
St Bk of India 491.55 (3.12%)
Sun Pharma.Inds. 757.55 (1.86%)
Tata Consumer 772.15 (1.51%)
Tata Motors 493.90 (2.51%)
Tata Steel 1173.00 (2.11%)
TCS 3626.90 (1.18%)
Tech Mahindra 1604.80 (1.79%)
Titan Company 2405.55 (1.05%)
UltraTech Cem. 7423.95 (1.71%)
UPL 728.10 (0.16%)
Wipro 641.70 (1.47%)
NATCOPHARM

Natco Pharma Ltd.

₹834.7
Not a customer?

Open free demat account
& trade instantly

Investment Ratings

  • Master Rating:
  • Natco Pharma has an operating revenue of Rs. 1,474.00 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 28% is great, ROE of 10% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 22 which is a POOR score indicating inconsistency in earnings, a RS Rating of 7 which is FAIR indicating the recent price performance, Buyer Demand at D which indicates heavy supply, Group Rank of 147 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Analyst Recommendation : HOLD

Natco Pharma Ltd Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Ratings

Eps And Sales Estimates

Natco Pharma Ltd Synopsis

NSE-Medical-Diversified

Natco Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1653.50 Cr. and Equity Capital is Rs. 36.50 Cr. for the Year ended 31/03/2021. Natco Pharma Ltd. is a Public Limited Listed company incorporated on 19/09/1981 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24230TG1981PLC003201 and registration number is 003201.
  • Market Cap

    INR 15,207.90 Cr

  • Sales

    INR 1,366.60 Cr

  • Shares in Float

    9.30 Cr

  • No of Funds

    219 K

  • Yield

    0.43%

  • Book Value

    3.67

  • U/D Vol Ratio

    0.7

  • LTDebt/Equity

    0%

  • Alpha

    -0.1

  • Beta

    0.35

Natco Pharma Ltd Ownership
Natco Pharma Ltd Management

Natco Pharma Ltd Financials

INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Total ShareHolders Funds Annual Cr 4091.13869.53563.23125.41699.7
Fixed Assets Annual Cr 2229.32092.31852.41495.31165.2
Total Non Current Assets Annual Cr 2591.52406.82088.716821312
Total Current Assets Annual Cr 21612239.92267.42054.21035.1
Total Assets Annual Cr 4752.54646.74356.13736.22347.1
INDICATORMar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Book Value Per Share Annual Rs 224.1698212.6098195.2438169.398297.404
ROE Annual % 7.5612.2618.7222.3329.11
ROCE Annual % 9.5215.1423.7528.4437.5
Total Debt to Total Equity Annual -----
EBDIT Annual Margin % 31.3639.247.6446.2736.01

Natco Pharma Ltd Technicals

EMA & SMA

CURRENT PRICE

834.7 (1.46)

    • Bullish Moving Averages 5
    • Bearish Moving Averages 11

EMA

  • 20 Day

    835.78

  • 50 Day

    861.28

  • 100 Day

    891.39

  • 200 Day

    933.41

Natco Pharma Ltd Resistance and support

826.45 PIVOT

  • First Resistance

    834.9

  • Second Resistance

    847.15

  • Third Resistance

    855.6

  • First Support

    814.2

  • Second Support

    805.75

  • Third Support

    793.5

  • RSI

    47.57

  • MFI

    46.03

  • MACD

    -6.56

  • MACD signal line

    -9.43

Natco Pharma Ltd Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 307,416 24,427,275 79.46%
Week 274,491 17,556,444 63.96%
1 Month 252,224 12,144,592 48.15%
6 Month 375,470 20,166,503 53.71%

Natco Pharma Ltd Price change analysis

-36.8

Over 1 month

Low High
792.3 881.6

-139.7

Over 3 month

Low High
792.3 988.9

-236

Over 6 months

Low High
792.3 1189

-135.7

Over Year

Low High
771 1189

Similar Stocks

News

Natco Pharma Ltd - 524816 - Compliances-Reg. 39 (3) - Detail

Details of Loss of Share certificates Read More

Natco Pharma launches novel drug for colorectal, gastric can

Natco Pharma on Thursday said it has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorecta Read More

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 3

NATCO launches Tipanat tablets in India, for the treatment of advanced colorectal and gastric cancer Read More

Natco to step up focus on niche products products in US mark

Strategy mainly focussed on products involving intricate chemistry, complex manufacturing process' Read More

NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Detai

issue of duplicate share certificate Read More

Blogs

FAQs

Stock Directory-

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All 0-9